Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
Belshe
Robert B
RB
Saint Louis University, St. Louis, Missouri 63110, USA. belsherb@slu.edu
Newman
Frances K
FK
Anderson
Edwin L
EL
Wright
Peter F
PF
Karron
Ruth A
RA
Tollefson
Sharon
S
Henderson
Frederick W
FW
Meissner
H Cody
HC
Madhi
Shabir
S
Roberton
Don
D
Marshall
Helen
H
Loh
Richard
R
Sly
Peter
P
Murphy
Brian
B
Tatem
Joanne M
JM
Randolph
Valerie
V
Hackell
Jill
J
Gruber
William
W
Tsai
Theodore F
TF
D000281:Administration, Intranasal; D000914:Antibodies, Viral / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D022241:Parainfluenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010253:Respirovirus Infections / Q000276:immunology / Q000517:prevention & control; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology; D017201:Virus Shedding
D000914:Antibodies, Viral; D022241:Parainfluenza Vaccines; D022261:Respiratory Syncytial Virus Vaccines; D017778:Vaccines, Combined